112 related articles for article (PubMed ID: 30223121)
1. Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.
Meyer M; Foulquier S; Dupuis F; Flament S; Grimaud L; Henrion D; Lartaud I; Monard G; Grillier-Vuissoz I; Boisbrun M
Eur J Med Chem; 2018 Oct; 158():334-352. PubMed ID: 30223121
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.
Mizuno CS; Chittiboyina AG; Shah FH; Patny A; Kurtz TW; Pershadsingh HA; Speth RC; Karamyan VT; Carvalho PB; Avery MA
J Med Chem; 2010 Feb; 53(3):1076-85. PubMed ID: 20073471
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Heemstra RJ; Bigge CF; Chen J; Ciske FA; Davis JA; Ellis T; Esmaeil N; Flynn D; Han S; Jalaie M; Ohren JF; Powell NA
Bioorg Med Chem Lett; 2013 Feb; 23(3):767-72. PubMed ID: 23265881
[TBL] [Abstract][Full Text] [Related]
4. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.
Agelis G; Resvani A; Durdagi S; Spyridaki K; Tůmová T; Slaninová J; Giannopoulos P; Vlahakos D; Liapakis G; Mavromoustakos T; Matsoukas J
Eur J Med Chem; 2012 Sep; 55():358-74. PubMed ID: 22889560
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.
Zhang J; Hao QQ; Liu X; Jing Z; Jia WQ; Wang SQ; Xu WR; Cheng XC; Wang RL
Oncotarget; 2017 Apr; 8(15):25612-25627. PubMed ID: 28445965
[TBL] [Abstract][Full Text] [Related]
6. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites.
Schupp M; Lee LD; Frost N; Umbreen S; Schmidt B; Unger T; Kintscher U
Hypertension; 2006 Mar; 47(3):586-9. PubMed ID: 16365190
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Filzen GF; Flynn D; Bigge CF; Chen J; Davis JA; Dudley DA; Edmunds JJ; Esmaeil N; Geyer A; Heemstra RJ; Jalaie M; Ohren JF; Ostroski R; Ellis T; Schaum RP; Stoner C
J Med Chem; 2011 Jun; 54(12):4219-33. PubMed ID: 21557540
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor.
Tilley DG; Nguyen AD; Rockman HA
Biochem Biophys Res Commun; 2010 Jun; 396(4):921-6. PubMed ID: 20460106
[TBL] [Abstract][Full Text] [Related]
9. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.
Zhang J; Liu X; Wang SQ; Liu GY; Xu WR; Cheng XC; Wang RL
J Biomol Struct Dyn; 2017 Sep; 35(12):2665-2680. PubMed ID: 27602589
[TBL] [Abstract][Full Text] [Related]
10. Facile and efficient syntheses of a series of N-benzyl and N-biphenylmethyl substituted imidazole derivatives based on (E)-urocanic acid, as angiotensin II AT1 receptor blockers.
Agelis G; Kelaidonis K; Resvani A; Kalavrizioti D; Androutsou ME; Plotas P; Vlahakos D; Koukoulitsa C; Tselios T; Mavromoustakos T; Matsoukas J
Molecules; 2013 Jun; 18(7):7510-32. PubMed ID: 23807577
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor γ regulates angiotensin II-induced catalase downregulation in adventitial fibroblasts of rats.
Yang W; Zhang J; Wang H; Shen W; Gao P; Singh M; Fang N
FEBS Lett; 2011 Mar; 585(5):761-6. PubMed ID: 21295034
[TBL] [Abstract][Full Text] [Related]
12. Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers.
Agelis G; Resvani A; Koukoulitsa C; Tůmová T; Slaninová J; Kalavrizioti D; Spyridaki K; Afantitis A; Melagraki G; Siafaka A; Gkini E; Megariotis G; Grdadolnik SG; Papadopoulos MG; Vlahakos D; Maragoudakis M; Liapakis G; Mavromoustakos T; Matsoukas J
Eur J Med Chem; 2013 Apr; 62():352-70. PubMed ID: 23376252
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
[TBL] [Abstract][Full Text] [Related]
14. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
16. High glucose enhances angiotensin-II-mediated peroxisome proliferation-activated receptor-gamma inactivation in human coronary artery endothelial cells.
Min Q; Bai YT; Jia G; Wu J; Xiang JZ
Exp Mol Pathol; 2010 Feb; 88(1):133-7. PubMed ID: 19796634
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.
Wang JL; Zhang J; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
Eur J Med Chem; 2012 Mar; 49():183-90. PubMed ID: 22309912
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives.
Shah DI; Sharma M; Bansal Y; Bansal G; Singh M
Eur J Med Chem; 2008 Sep; 43(9):1808-12. PubMed ID: 18158200
[TBL] [Abstract][Full Text] [Related]
19. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Nenicu A; Körbel C; Gu Y; Menger MD; Laschke MW
Hum Reprod; 2014 May; 29(5):1011-24. PubMed ID: 24578472
[TBL] [Abstract][Full Text] [Related]
20. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]